Document:

Exhibit 10.6

    

    

    WSHARES BITCOIN FUND

    SUBSCRIPTION AGREEMENT

    

    

    This Subscription Agreement (this “Agreement”) is dated ____, 2022, by and between wShares Bitcoin Fund, a Delaware statutory trust (the “Trust”) and the undersigned
      identified on the signature page hereto (the “Investor”).

    WHEREAS, the Trust has authorized the sale and issuance to certain investors of up to an aggregate of [    ] common shares
      (the “Shares”), par value $0.01 per Share, of the Trust for a purchase price of $[    ] per share (the “Purchase Price”);

    WHEREAS, the offering and sale of the Shares (the “Offering”) are being made pursuant to (1) an effective Registration Statement on Form S-1 (including the Prospectus contained therein (the “Base Prospectus”), the “Registration Statement”) filed by the Trust with the Securities and Exchange Commission (the “Commission”), (2) if applicable, certain “free writing prospectuses” (as that term is defined in Rule 405 under the Securities Act of 1933, as amended (the “Act”)), that have been or will be filed with the Commission and delivered to the Investor on or prior to the date hereof and (3) a Prospectus Supplement (the
      “Prospectus Supplement” and together with the Base Prospectus, the “Prospectus”) containing certain supplemental information regarding the Shares and terms of the Offering that will be filed with the Commission and delivered to the Investor (or made available to the Investor by the filing by the Trust
      of an electronic version thereof with the Commission);

    WHEREAS, the Trust has entered into an Underwriting Agreement, dated [    ], 2022 (the “Underwriting Agreement”), with Oasis Pro Markets LLC, a FINRA-registered broker/dealer, to act as the underwriter of the Shares in the Offering (the “Underwriter”);

    WHEREAS, the Trust, the Underwriter and Signature Bank (the “Escrow Agent”) have entered into an Escrow Agreement, dated [    ], 2022 (the “Escrow Agreement”), pursuant
      to which Signature Bank has agreed to serve as the Escrow Agent in connection with the Offering; and

    WHEREAS, the Investor desires to purchase a certain amount of Shares from the Trust.

    NOW, THEREFORE, in consideration of the foregoing and of the covenants contained herein, the sufficiency of which is
      hereby mutually accepted, the parties hereby agree as follows:

    1.  The Trust and the Investor agree that the Investor will purchase from the Trust and the Trust will issue and sell to
      the Investor the Shares set forth below for the aggregate purchase price set forth below, which shall be equal to the product of (x) the aggregate number of Shares the Investor has agreed to purchase and (y) the Purchase Price.  The Shares shall be
      purchased pursuant to the Terms and Conditions for Purchase of Shares attached hereto as Annex I and incorporated herein by this reference as if fully set forth
      herein.

    2.  The Investor acknowledges that (i) the Shares are being offered by the Underwriter on a “best efforts” basis; (ii)
      there is no minimum offering amount of Shares in the Offering; and (ii) prior to the Investor’s purchase of any Shares, the Trust, in its sole discretion, elects not proceed with the Offering, in which case, the Trust will return the aggregate
      Purchase Price paid for Shares by the Investor without interest within three (3) Business Days of making such determination. The Investor shall only be entitled to receive a refund of its subscription in the event the Trust, in its sole discretion,
      may not proceed with the Offering.

    
      
        

    

    
    

    

    3.  The settlement of the Shares purchased by the Investor shall be by delivery through The Depository Trust Company (“DTC”), registered in the name of Cede & Co., as DTC’s nominee, and released by Broadridge Corporate Issuer Solutions, Inc., the Trust’s transfer agent
      (the “Transfer Agent”), to the Investor at the Closing (as defined in Section 3.1 of Annex I hereto).

    NO LATER THAN ONE (1) BUSINESS DAY AFTER THE EXECUTION OF THIS AGREEMENT BY THE INVESTOR AND THE
      TRUST, THE INVESTOR SHALL:

    	

          	(I)	
            DIRECT THE BROKER-DEALER AT WHICH THE ACCOUNT OR ACCOUNTS TO BE CREDITED WITH THE SHARES ARE MAINTAINED TO SET UP A DEPOSIT/WITHDRAWAL AT CUSTODIAN (“DWAC”)
              INSTRUCTING THE TRANSFER AGENT TO CREDIT SUCH ACCOUNT OR ACCOUNTS WITH THE SHARES, AND

          

    	

          	(II)	
            REMIT BY CHECK (MADE PAYABLE TO THE ORDER OF “[         ], AS ESCROW AGENT FOR WSHARES BITCOIN FUND”) OR WIRE TRANSFER THE AMOUNT OF FUNDS EQUAL TO THE
              AGGREGATE PURCHASE PRICE FOR THE SHARES BEING PURCHASED BY THE INVESTOR TO THE FOLLOWING ACCOUNT:

          

    

    

    [Escrow Account Details]

    

    

    IT IS THE INVESTOR’S
          RESPONSIBILITY TO (A) MAKE THE NECESSARY WIRE TRANSFER IN A TIMELY MANNER AND (B) ARRANGE FOR SETTLEMENT BY WAY OF DWAC IN A TIMELY MANNER.  IF THE INVESTOR DOES NOT DELIVER THE AGGREGATE PURCHASE PRICE FOR THE SHARES OR DOES NOT MAKE PROPER
          ARRANGEMENTS FOR SETTLEMENT IN A TIMELY MANNER, THE SHARES MAY NOT BE DELIVERED AT CLOSING TO THE INVESTOR OR THE INVESTOR MAY BE EXCLUDED FROM THE CLOSING ALTOGETHER.

    4.  The Investor represents that, except as set forth below, (a) it has had no position, office or other material
      relationship within the past three years with the Trust or persons known to it to be affiliates of the Trust, (b) it is not a FINRA member or an Associated Person (as such term is defined under the FINRA Membership and Registration Rules Section
      1011) as of the Closing, and (c) neither the Investor nor any group of Investors (as identified in a public filing made with the Commission) of which the Investor is a part in connection with the Offering of the Shares, acquired, or obtained the
      right to acquire, 9.9% or more of the Common Stock (or securities convertible into or exercisable for Common Stock) or the voting power of the Trust on a post-transaction basis.

    5.  The Investor represents that it has received (or otherwise had made available to it by the filing by the Trust of an
      electronic version thereof with the Commission) the Base Prospectus, dated [DATE], which is a part of the Trust’s Registration Statement, the documents incorporated by reference therein and any free writing prospectus (collectively, the “Disclosure Package”), prior to or in connection with the receipt of this Agreement.  The Investor acknowledges that, prior to the delivery of this Agreement
      to the Trust, the Investor will receive certain additional information regarding the Offering, including pricing information (the “Offering Information”).
      Such information may be provided to the Investor by any means permitted under the Act, including the Prospectus Supplement, a free writing prospectus and oral communications.

    
      - 2 -

      
        

    

    

    

    6.  No offer by the
      Investor to buy Shares will be accepted and no part of the Purchase Price will be delivered to the Trust until the Investor has received the Offering Information and the Trust has accepted such offer by countersigning a copy of this Agreement, and
      any such offer may be withdrawn or revoked by the Investor, without obligation or commitment of any kind, at any time prior to the Trust (or an Underwriter on behalf of the Trust) sending (orally, in writing or by electronic mail) notice of its
      acceptance of such offer. An indication of interest will involve no obligation or commitment of any kind until the Investor has been delivered the Offering Information and this Agreement is accepted and countersigned by or on behalf of the Trust.
      Upon the delivery by the Trust to the Investor of the Offering Information, and acceptance and execution of the Agreement by the Trust, Sponsor and Investor, the Investor cannot withdraw its Agreement.

    7.  It is expressly understood and agreed by the Investor that:

    (a)  this Agreement is executed and delivered on behalf of the Trust by Wilshire Phoenix Funds LLC, as
      the sponsor (the “Sponsor”) of the Trust, not individually or personally, but solely as Sponsor of the Trust in the exercise of the powers and authority
      conferred and vested in it;

    (b)  the representations, covenants, undertakings and agreements herein made on the part of the Trust
      are made and intended not as personal representations, undertakings and agreements by the Sponsor but are made and intended for the purpose of binding only the Trust;

    (c)  nothing herein contained shall be construed as creating any liability on the Sponsor, individually
      or personally, to perform any covenant of the Trust either expressed or implied contained herein, all such liability, if any, being expressly waived by the parties hereto and by any person claiming by, through or under the parties hereto; and

    (d)  under no circumstances shall the Sponsor be personally liable for the payment of any indebtedness
      or expenses of the Trust or be liable for the breach or failure of any obligation, duty, representation, warranty or covenant made or undertaken by the Trust under this Agreement or any other related document.

    

    

    [The remainder of this page is intentionally left
        blank.]

    
      - 3 -

      
        

    

    

    

    	
            Number of Shares:

          	 	 
	
            Purchase Price Per Share: $

          	 	 
	
            Aggregate Purchase Price: $

          	 	 

    

    

    Please confirm that the foregoing correctly sets forth the agreement between us by signing in the space provided below for
      that purpose.

    	 	
            Dated as of:

          	 
	 	 	 
	 	 	 
	 	 	 
	 	
            INVESTOR

          	 
	 	 	 
	 	
            By:

          	 	 
	 	
            Print Name:

          	 	 
	 	
            Title:

          	 	 
	 	
            Address:

          	 	 
	 	 	 	 
	 	 	 	 
	 	
            Email:

          	 	 

    

    

    

    

    

    

    

    

    Agreed and Accepted

    This [  ] day of [   ], 20[  ]:

    

    

    

    

    	
            WSHARES BITCOIN FUND

          	 
	 	 
	
            By:

          	
            Wilshire Phoenix Funds LLC,

          	 
	 	
            as Sponsor of the Trust

          	 
	 	 	 
	
            By:

          	 	 
	 	
            Name:

          	 	 
	 	
            Title:

          	 	 

    

    

    

    

    

    

    
      - 4 -

      
        

    

    ANNEX I

    TERMS AND CONDITIONS FOR PURCHASE OF SHARES

    1.  Authorization and Sale of the
        Shares.  Subject to the terms and conditions of this Agreement, the Trust has authorized the sale of the Shares.

    2.  Agreement to Sell and Purchase the Shares; Underwriter.

    2.1  At the Closing (as
      defined in Section 3.1), the Trust will sell to the Investor, and the Investor will purchase from the Trust, upon the terms and conditions set forth herein, the
      number of Shares set forth on the last page of the Agreement to which these Terms and Conditions for Purchase of Shares are attached as Annex I (the “Signature Page”) for the aggregate purchase price therefor set forth on the Signature Page.

    2.2  The Trust proposes to
      enter into substantially this same form of Subscription Agreement with certain other investors (the “Other Investors”) and expects to complete sales of
      Shares to them, in each case at the same Purchase Price per Share referenced on the Signature Page. The Investor and the Other Investors are hereinafter sometimes collectively referred to as the “Investors,” and this Agreement and the Subscription Agreements executed by the Other Investors are hereinafter sometimes collectively referred to as the “Agreements.”

    2.3  Investor acknowledges
      that the Trust has agreed to pay Oasis Pro Markets LLC (the “Underwriter”) a fee (the “Underwriter Fee”) in respect of the sale of Shares to the Investor.

    2.4  The Trust has entered
      into an Underwriting Agreement, dated [   ], 2022 (the “Underwriting Agreement”), with the Underwriter that contains certain representations, warranties,
      covenants and agreements of the Trust.  By countersigning this Subscription Agreement, the Trust permits the Investor to rely upon such representations, warranties, covenants and agreements of the Trust contained in the Underwriting Agreement.

    3.  Closings and Delivery of the Shares and Funds.

    3.1  Closing.  The
      completion of the purchase and sale of the Shares, or a portion thereof, (the “Closing”) shall occur at a place and time (the “Closing Date”) to be specified by the Trust and the Underwriter, and of which the Investors will be notified in advance by the Underwriter, in accordance with Rule 15c6-1
      promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  At the Closing, (a) the Trust shall irrevocably instruct
      Broadridge Corporate Issuer Solutions, the Trust’s transfer agent (the “Transfer Agent”) to deliver to the Investor the number of Shares set forth on the
      Signature Page pursuant to the information provided by the Investor in Exhibit A and (b) the aggregate purchase price for the Shares being purchased by the Investor
      will be delivered from the Escrow Account (as defined below) to the Trust.

    3.2  Conditions to the Trust’s Obligations.

    (a)  The Trust’s obligation to issue and sell the Shares to the Investor shall be subject to: (i) the receipt by the Trust
      of the purchase price for the Shares being purchased hereunder as set forth on the Signature Page; (ii) the accuracy of the representations and warranties made by the Investor and the fulfillment of those undertakings of the Investor to be fulfilled
      prior to the Closing Date; and (iii) the Trust’s sole determination to conduct the Offering, which determination shall be made no later than five (5) Business Days after this Agreement is fully executed.

    
      - 5 -

      
        

    

    

    

    (b)  Conditions to the
        Investor’s Obligations.  The Investor’s obligation to purchase the Shares as set forth on the Signature Page will be subject to the accuracy of the representations and warranties made by the Trust and the fulfillment of those undertakings
      of the Trust to be fulfilled prior to the Closing Date, including without limitation, those contained in the Underwriting Agreement, and to the condition that the Underwriters shall not have: (a) terminated the Underwriting Agreement pursuant to the
      terms thereof or (b) determined that the conditions to the closing in the Underwriting Agreement have not been satisfied.

    (c)  Disclaimer Regarding
        Partial Settlement. The Investor’s obligations are expressly not conditioned on the purchase by any or all of the Other Investors of the Shares that they have agreed to purchase from the Trust or the sale by the Trust of any specified
      aggregate number of Shares.

    3.3  Delivery of this Agreement. 
      Prior to the Closing Date, the Investor shall complete and execute this Agreement and deliver it to the Underwriter at the address set forth below for forwarding to the Trust:

    Oasis Pro Markets LLC

    1 Thorndal Circle

    Darien, CT 06820

    Attn: Pat LaVecchia

    3.4  Delivery of Funds.

    (a)  No later than one (1) Business Day after the execution of this Agreement by the Investor and the Trust, the Investor
      shall remit by check (made payable to the order of “[       ], as Escrow Agent for wShares Bitcoin Fund”) or wire transfer the amount of funds equal to the aggregate purchase price for the Shares being purchased by the Investor to the following
      non-interest bearing escrow account (the “Escrow Account”) designated by the Trust and the Underwriters pursuant to the terms of that certain Escrow
      Agreement (the “Escrow Agreement”), dated as of [DATE], by and among the Trust, the Underwriters and [         ], as escrow agent (the “Escrow Agent”):

    [Escrow Account Details]

    (b)  Such funds shall be held in escrow until the Closing and delivered by the Escrow Agent on behalf of the Investors to
      the Trust upon the satisfaction, in the sole judgment of the Underwriters and the Trust, of the conditions set forth in Section 3.2(b) hereof.  The Underwriters
      shall have no rights in or to any of the escrowed funds, unless the Underwriters and the Escrow Agent are notified in writing by the Trust in connection with the Closing that a portion of the escrowed funds shall be applied to the Underwriter Fee.

    (c)  No later than one (1) business day after the execution of this Agreement, Investor shall also furnish to the Underwriters a completed W-9 form (or, in the case of an Investor who is not a United States citizen or resident, a W-8 form).

    
      - 6 -

      
        

    

    

    

    3.5  Delivery of Shares.   No
      later than one (1) business day after the execution of this Agreement by the Investor and the Company, the Investor shall direct the broker-dealer at which the account or accounts to be credited with the Shares being purchased by such Investor are
      maintained, which broker/dealer shall be a DTC participant, to set up a Deposit/Withdrawal at Custodian (“DWAC”) instructing the Transfer Agent to credit
      such account or accounts with the Shares on the settlement date.  Such DWAC shall indicate the settlement date for the deposit of the Shares, which date shall be provided to the Investor by the Underwriters.  Simultaneously with the delivery to the
      Trust by the Escrow Agent of the funds held in escrow pursuant to Section 3.3 above, the Trust shall direct the Transfer Agent to credit the Investor’s account or
      accounts with the Shares pursuant to the information contained in the DWAC.

    4.  Representations, Warranties and Covenants of the Investor.

    The Investor acknowledges, represents and warrants to, and agrees with, the Trust and the Underwriters that:

    4.1  The Investor (a) is
      knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to, investments in shares presenting an investment decision like that involved in the purchase of the Shares, including investments in securities
      issued by the Trust and investments in comparable companies, (b) has answered all questions on the Signature Page and the Investor Questionnaire and the answers thereto are true and correct as of the date hereof and will be true and correct as of the
      Closing Date and (c) in connection with its decision to purchase the number of Shares set forth on the Signature Page, has received and is relying solely upon (i) the Disclosure Package and the documents incorporated by reference therein and (ii) the
      Offering Information;

    4.2  (a) No action has
      been or will be taken in any jurisdiction outside the United States by the Trust or the Underwriters that would permit an offering of the Shares, or possession or distribution of offering materials in connection with the issue of the Shares in any
      jurisdiction outside the United States where action for that purpose is required, (b) if the Investor is outside the United States, it will comply with all applicable laws and regulations in each foreign jurisdiction in which it purchases, offers,
      sells or delivers Shares or has in its possession or distributes any offering material, in all cases at its own expense and (c) the Underwriters are not authorized to make and has not made any representation, disclosure or use of any information in
      connection with the issue, placement, purchase and sale of the Shares, except as set forth or incorporated by reference in the Base Prospectus or the Prospectus Supplement;

    4.3  The Investor has
      full right, power, authority and capacity to enter into this Agreement and to consummate the transactions contemplated hereby and has taken all necessary action to authorize the execution, delivery and performance of this Agreement, and (b) this
      Agreement constitutes a valid and binding obligation of the Investor enforceable against the Investor in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar
      laws affecting creditors’ and contracting parties’ rights generally and except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law) and except
      as to the enforceability of any rights to indemnification or contribution that may be violative of the public policy underlying any law, rule or regulation (including any federal or state securities law, rule or regulation);

    4.4  The Investor
      understands that nothing in this Agreement, the Prospectus or any other materials presented to the Investor in connection with the purchase and sale of the Shares constitutes legal, tax or investment advice.  The Investor has consulted such legal,
      tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of Shares; and

    
      - 7 -

      
        

    

    

    

    4.5  Since the date on
      which the Underwriters first contacted such Investor about the Offering, the Investor has not engaged in any transactions in the securities of the Trust (including, without limitation, any Short Sales (as defined below) involving the Company’s
      securities) and has not violated its obligations of confidentiality.  Each Investor covenants that it will not engage in any transactions in the securities of the Trust (including Short Sales) or disclose any information about the contemplated
      offering (other than to its advisors that are under a legal obligation of confidentiality) prior to the time that the transactions contemplated by this Agreement are publicly disclosed.  Each Investor agrees that it will not use any of the Shares
      acquired pursuant to this Agreement to cover any short position in the Shares if doing so would be in violation of applicable securities laws.  For purposes hereof, “Short Sales” include, without limitation, all “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward
      sales contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h) under the Exchange Act) and similar arrangements (including on a total return basis), and sales and other transactions through non-US
      broker dealers or foreign regulated brokers.

    5.  Survival of Representations,
        Warranties and Agreements; Third Party Beneficiary.  Notwithstanding any investigation made by any party to this Agreement or by the Underwriters, all covenants, agreements, representations and warranties made by the Trust and the Investor
      herein will survive the execution of this Agreement, the delivery to the Investor of the Shares being purchased and the payment therefor.  The Underwriters shall be third party beneficiaries with respect to the representations, warranties and
      agreements of the Investor in Section 4 hereof.

    6.  Notices.  All
      notices, requests, consents and other communications hereunder will be in writing, will be mailed (a) if within the domestic United States by first-class registered or certified airmail, or nationally recognized overnight express courier, postage
      prepaid, or by facsimile; (b) electronically, or (c) if delivered from outside the United States, by International Federal Express or facsimile, and will be deemed given (i) if delivered by first-class registered or certified mail domestic, three
      business days after so mailed, (ii) if delivered by nationally recognized overnight carrier, one business day after so mailed, (iii) if delivered by International Federal Express, two business days after so mailed and (iv) if delivered by facsimile,
      upon electric confirmation of receipt and will be delivered and addressed as follows:

    (a)  if to the Trust, to:

    wShares Bitcoin Fund

    2 Park Avenue, 20th Floor

    New York, New York 10016

    Attention: William Cai

    Email: will@wilshirephoenix.com

    

    

    (b)  if to the Investor, at its address on the Signature Page hereto, or at such other address or addresses as may have been furnished to the Company in writing.

    7.  Changes.  This
      Agreement may not be modified or amended except pursuant to an instrument in writing signed by the Company and the Investor.

    
      - 8 -

      
        

    

    

    

    8.  Headings.  The
      headings of the various sections of this Agreement have been inserted for convenience of reference only and will not be deemed to be part of this Agreement.

    9.  Severability.  In
      case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby.

    10.  Governing Law.  This
      Agreement will be governed by, and construed in accordance with, the internal laws of the State of New York, without giving effect to the principles of conflicts of law that would require the application of the laws of any other jurisdiction.

    11.  Counterparts.  This
      Agreement may be executed in two or more counterparts, each of which will constitute an original, but all of which, when taken together, will constitute but one instrument, and will become effective when one or more counterparts have been signed by
      each party hereto and delivered to the other parties.  The Company and the Investor acknowledge and agree that the Company shall deliver its counterpart to the Investor along with the Prospectus Supplement (or the filing by the Company of an
      electronic version thereof with the Commission).

    12.  Confirmation of Sale. 
      The Investor acknowledges and agrees that such Investor’s receipt of the Company’s counterpart to this Agreement, together with the Prospectus Supplement (or the filing by the Company of an electronic version thereof with the Commission), shall
      constitute written confirmation of the Company’s sale of Shares to such Investor.

    13.  Press Release.  The
      Trust and the Investor agree that the Trust or the Sponsor may issue a press release announcing the Offering and disclosing all material terms and conditions of the Offering prior to the opening of the financial markets in New York City; provided that neither the Trust nor the Sponsor shall publicly disclose the name of the Investor in any press release, public announcement, or in any filing
      with the Commission without the prior written consent of such Investor, except as required by applicable law, in which case the Trust or the Sponsor, as applicable, will provide the Investor with prior written notice of any such disclosure.

    14.  Termination.  In the
      event that the Underwriting Agreement is terminated by the Underwriters pursuant to the terms thereof, this Agreement shall terminate without any further action on the part of the parties hereto.

    

    

    [The remainder of this page is intentionally left blank.]

    

    

    
      - 9 -

      
        

    

    Exhibit A

    

    

    INVESTOR QUESTIONNAIRE

    Pursuant to Section 3 of Annex I to the Agreement, please provide us with the following information:

    

    

    	
            1.

          	
            The exact name of Investor:

          	 	 
	 	 	 	 
	
            2.

          	
            The mailing address of the Investor:

          	 	 
	 	 	 	 
	
            3.

          	
            The Social Security Number or Tax Identification Number of the Investor:

          	 	 
	 	 	 	 
	
            4.

          	
            Name of DTC Participant (broker-dealer at which the account or accounts to be credited with the Shares are maintained):

          	 	 
	 	 	 	 
	
            5.

          	
            DTC Participant Name

          	 	 
	 	 	 	 
	
            6.

          	
            DTC Participant Email and Telephone Number:

          	 	 
	 	 	 	 
	
            7.

          	
            Name of Investor Account at DTC Participant being credited with the Shares**:

          	 	 
	 	 	 	 
	
            8.

          	
            Account Number at DTC Participant being credited with the Shares:

          	 	 
	 	 	 	 

    

    

    

    

    ** In order to ensure timely settlement, please cause your broker or custodian to include the name of the ultimate beneficial holder or sub-account to which the Shares shall be credited in the DWAC authorization
          request.Exhibit 10.2

 

ASSET PURCHASE AGREEMENT

 

Among

 

CRITICAL MASS INDUSTRIES LLC (“CMI”)

 

and

 

Critical Mass Industries, Inc the
sole member of CMI (“CMI, Inc”),

 

and

 

JOHN KNAPP as controlling shareholder
of CMI, Inc (“Knapp”)

 

and

 

GOOD MEDS, INC. (“Seller”)

 

and

 

CRYOMASS TECHNOLOGIES., formerly
Redwood Green Corp.

and Andina Gold Corp., (“Parent”) dated as of

December 31, 2021

 

     

     

    

 

ASSET PURCHASE AGREEMENT

 

This Asset Purchase Agreement (this "Agreement"),
dated as of December 31, 2021, is entered into by and among Critical Mass Industries LLC, a Colorado limited liability company ("CMI"
or “Buyer”), Critical Mass Industries, Inc., a Colorado Corporation, the sole member of CMI (“CMI, Inc.”),
John Knapp, the sole or controlling shareholder of CMI, Inc. (“Knapp”), Good Meds, Inc., a Colorado corporation, formerly
known as Good Acquisition Co. ("Seller") and wholly owned subsidiary of Andina Gold Corp., a Nevada corporation, formerly
Redwood Green Corp., and formerly known as First Colombia Development Corp., (“Parent”). CMI, CMI, Inc. and Knapp are
collectively referred to herein as the “Buyer Parties”, and all parties are hereto collectively referred to as “Parties.”

 

RECITALS

 

WHEREAS, on August
5, 2019, CMI, Inc. and its shareholders entered into a Plan of Partial Liquidation and Redemption Agreement (the “Plan”),
resulting in Knapp remaining the sole shareholder of CMI, Inc., and no other CMI, Inc. former shareholder having any further rights or
claims with respect to any form of ownership interest, economic or otherwise, in CMI, Inc.,

 

WHEREAS, on August
6, 2019, CMI, CMI Inc., and Seller (formerly known as Good Acquisition Co.) entered into a series of transactions pursuant to which Seller
purchased all of CMI’s interest in Good Holdco LLC and Good IPCO LLC (the “Original Purchase Transaction”), together
with certain assets, hereinafter referred to as the “Purchased Assets”)

 

WHEREAS, on August
5, 2019, CMI, Knapp and other parties entered into a Tax Indemnification Agreement with Parent and Buyer (“Tax Indemnification”),

 

WHEREAS, as part
of the Original Purchase Transaction, CMI retained Seller to provide various services memorialized in a consulting agreement, a marketing
agreement and an administrative services agreement (the “Transition Agreements”),

 

WHEREAS, on August
5, 2020, the Parties entered into an Asset Purchase Agreement (the “2020 APA”),

 

WHEREAS on May
13, 2021 the Parties mutually agreed to terminate and unwind the 2020 APA as a result of certain regulatory decisions beyond the Parties
control by replacing it with that certain Asset Purchase Agreement dated May 13, 2021 (“May 2021 APA”),

 

WHEREAS, the parties
hereby wish to terminate and unwind the May 2021 APA and, in lieu of it, the Parties are executing this Agreement, whereby Seller wishes
to sell and assign to Buyers, and Buyers wishes to purchase and assume from Seller, the rights of Seller to the Purchased Assets and the
Assumed Liabilities (as defined herein), subject to the terms and conditions set forth herein, and concurrently terminate or amend the
Transition Agreements;

 

NOW, THEREFORE,
in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

    2

     

    

 

ARTICLE I

PURCHASE AND SALE

 

Section 1.01
Termination of the May 2021 APA. The May 2021 APA is hereby terminated and the assets transferred at the signing of the May 2021 APA
hereby revert to Good Meds. Each of the Parties acknowledges and agrees that it hereby releases the other Parties of any obligations under
the May 2021 APA and waive any rights accrued under the May 2021 APA

 

Section 1.02.
Purchase and Sale of Assets. Subject to the terms and conditions set forth herein, (1) Seller shall sell, assign, transfer, convey
and deliver to Buyer, and Buyer shall purchase from Seller, all of Seller’s right, title and interest in the assets set forth on
Section 1.01 of the disclosure schedules ("Disclosure Schedules") attached hereto (the "Purchased Assets"),
and (2) Parent shall issue to Knapp 1,500,000 restricted shares of Parent common stock par value $0.001 per share (the "Parent
Shares") free and clear of any mortgage, pledge, lien, charge, security interest, claim or other encumbrance ("Encumbrance"),
which issuance shall be performed five working days from the date when the secured promissory note referenced in Section 1.04 (‘Note”)
is paid in full to Seller. For avoidance of any doubt, no shares shall be issued or due to Buyer if the entire purchase price is not paid
in full to Seller in satisfaction of the Note.

 

Section 1.03
Assumption of Liabilities. Subject to the terms and conditions set forth herein, Buyer shall assume and agree to pay, perform and
discharge the liabilities and obligations set forth on 1.02 of the Disclosure Schedules arising after the Closing (as defined herein)
connection with the Purchased Assets, but only to the extent that such liabilities and obligations do not relate to any breach, default
or violation by Seller on or prior to the Closing (collectively, the "Assumed Liabilities"). The Purchased Assets are
purchased “as is” and Buyer hereby waives any right to inspect or reject the Purchased Assets. Other than the Assumed Liabilities,
Buyer shall not assume any liabilities or obligations of Seller, Parent or affiliates of any kind, whether known or unknown, including,
without limitation, tax liabilities, contingent, matured or otherwise, whether currently existing or hereinafter created.

 

Section 1.04
Purchase Price. The aggregate purchase price (the “Purchase Price”) for the Purchased Assets shall be six million
US dollars ($6,000,000) Concurrent with the execution hereof, Buyer shall issue the Note in the form attached hereto as Exhibit A to Seller’s
satisfaction. Furthermore, any proceeds resulting from the disposition of any Buyer Parties assets after the date hereof shall be promptly
placed by the respective Buyer Parties in an escrow account agreeable to Seller, in favor of Seller, and in satisfaction of the Note,
even if such sale occurs before the Due Date of the Note. The terms of the escrow account agreement shall be in form and substance acceptable
to Seller. Buyer Parties will execute such documents as needed to establish the escrow account agreement.

 

Section 1.05
Withholding Tax. Buyer shall be entitled to deduct and withhold from the Purchase Price all taxes that Buyer may be required to deduct
and withhold under any applicable tax law. All such withheld amounts shall be treated as delivered to Seller hereunder.

 

    3

     

    

 

ARTICLE II

CLOSING

 

Section 2.01
Closing. This Agreement shall close on the earliest of on December 31, 2021 or concurrent with the last dated execution of the Agreement
by a Party and exchange of necessary instruments provided herein ("Closing"). The effective date of the agreement shall
be December 31, 2021. The consummation of a Closing under this Agreement shall be deemed to have occurred at 11:59 p.m. on the Closing
Date or 11:59 of December 31, 2021, whichever earliest.

 

Section 2.02 Closing Deliverables.

 

		(a)	As of the date hereof, Seller shall transfer Buyer the Purchased
Assets.

 

		(b)	As of the date hereof Buyer shall execute and deliver the Note.

 

		(c)	At Closing, and as it may be necessary and applicable from time to time, Buyer shall promptly execute
such documents needed by Seller to perfect a security interest in Buyer’s assets, receivables, bank accounts, in any jurisdiction
as requested by Seller from time to time.

 

		(d)	At the Closing, Seller shall deliver to Buyer the following:

 

		(i)	a bill of sale in form and substance satisfactory to Buyer (the
"Bill of Sale") and duly executed by Good Meds, transferring the Purchased Assets to Buyer;
	 	 	 

		(ii)	a certificate pursuant to Treasury Regulations Section 1.1445-2(b)
that Knapp is not a foreign person within the meaning of Section 1445 of the Internal Revenue Code duly executed by Knapp;

 

		(iii)	such other customary instruments of transfer, assumption, filings
or documents, in form and substance reasonably satisfactory to Seller, as may be required to give effect to this Agreement.

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF BUYER

 

Buyer represent
and warrant to Seller that the statements contained in this Article III are true and correct as of the date hereof. For purposes of this
Article ARTICLE III, "Buyer’s knowledge," "knowledge of Buyer" and any similar phrases shall mean the actual
or constructive knowledge of Knapp.

 

Section 3.01
Organization and Authority of CMI; Enforceability. Each of CMI and the Subsidiaries are limited liability companies duly organized,
validly existing and in good standing under the laws of the state of Colorado. Knapp and CMI has full corporate power and authority to
enter into this Agreement and the documents to be delivered hereunder, to carry out its obligations hereunder and to consummate the transactions
contemplated hereby. The execution, delivery and performance by Knapp and CMI of this Agreement and the documents to be delivered hereunder
and the consummation of the transactions contemplated hereby have been duly authorized by all requisite corporate action on the part of
CMI. This Agreement and the documents to be delivered hereunder have been duly executed and delivered by Buyer, and (assuming due authorization,
execution and delivery by Seller) this Agreement and the documents to be delivered hereunder constitute legal, valid and binding obligations
of Buyer Parties, enforceable against Buyer Parties in accordance with their respective terms.

 

    4

     

    

 

Section 3.02
No Conflicts; Consents. The execution, delivery and performance by Buyer Parties of this Agreement and the documents to be delivered
hereunder, and the consummation of the transactions contemplated hereby, do not and will not: (a) violate or conflict with the certificate
of formation, operating agreement or other organizational documents of CMI and the Subsidiaries; (b) violate or conflict with any judgment,
order, decree, statute, law, ordinance, rule or regulation applicable to Buyer Parties, the Subsidiaries or the Purchased Assets; (c)
conflict with, or result in (with or without notice or lapse of time or both) any violation of, or default under, or give rise to a right
of termination, acceleration or modification of any obligation or loss of any benefit under any contract or other instrument to which
CMI or any Subsidiary is a party or to which any of the Purchased Assets are subject; or (d) result in the creation or imposition of any
Encumbrance on the Purchased Assets. No consent, approval, waiver or authorization is required to be obtained by any of the Parties from
any person or entity (including any governmental authority) in connection with the execution, delivery and performance by such Seller
of this Agreement and the consummation of the transactions contemplated hereby.

 

Section 3.03
Non-foreign Status. Knapp is not a "foreign person" as that term is used in Treasury Regulations Section 1.1445-2.

 

Section 3.04
Compliance with Laws. Knapp and CMI has complied, and is now complying, with all applicable state and local laws and regulations applicable
to ownership and use of the Purchased Assets.

 

Section 3.05
Legal Proceedings. Except as set forth in Section 3.10 of the Disclosure Schedule, there is no claim, action, suit, proceeding or
governmental investigation ("Action") of any nature pending or, to Buyer’s knowledge, threatened against or by
any Buyer Parties that challenges or seeks to prevent, enjoin, or otherwise delay the transactions contemplated by this Agreement. No
event has occurred, or circumstances exist that may give rise to, or serve as a basis for, any such Action.

 

Section 3.06
The Buyer Parties acknowledges that the Parent Shares will be issued pursuant to prospectus exemptions in the United States provided under
the Securities Act and acknowledge that:

 

		(a)	no securities commission or similar regulatory authority has
reviewed or passed on the merits of the Parent Shares;

 

		(b)	there is no government or other insurance covering the Parent Shares;

 

    5

     

    

 

		(c)	there are risks associated with the purchase of the Parent Shares;

 

		(d)	there may be restrictions on Knapp’s ability to resell
the Parent Shares or any Parent Shares issued upon conversion thereof, and it is the responsibility of Knapp to find out what those restrictions
are and to comply with them before selling any of the Parent Shares or any Parent Shares issued upon conversion thereof; and

 

		(e)	the Parent has advised that the Parent is relying on an exemption
from the requirements to provide the Buyer Parties with a prospectus and to sell securities through a person registered to sell securities
under the Securities Act and, as a consequence of acquiring securities pursuant to this exemption, certain protections, rights and remedies
provided by the Securities Act, including statutory rights of rescission or damages, will not be available to the Buyer Parties;

 

		(f)	no unusual effort has been made to prepare the market or to
create a demand for the Parent Shares.

 

		(g)	the Buyer Parties consent to the placement of a legend or legends
on any certificate or other document evidencing any of the Parent Shares setting forth or referring to the restrictions on transferability
and sale thereof imposed by law or by SEC.

 

Section 3.07
Brokers. No broker, finder or investment banker is entitled to any brokerage, finder's or other fee or commission in connection with
the transactions contemplated by this Agreement based upon arrangements made by or on behalf of any Buyer Party.

 

Section 3.08
Full Disclosure. No representation or warranty by Buyer Parties in this Agreement and no statement contained in the Disclosure Schedules
to this Agreement or any certificate or other document furnished or to be furnished to Seller pursuant to this Agreement contains any
untrue statement of a material fact, or omits to state a material fact necessary to make the statements contained therein, in light of
the circumstances in which they are made, not misleading.

 

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF
BUYER AND PARENT

 

Each of Seller
and Parent represents and warrants to Buyer Parties that the statements contained in this Article ARTICLE IV are true and correct as of
the date hereof. For purposes of this Article ARTICLE IV, "Seller's knowledge," "knowledge of Seller" and any similar
phrases shall mean the actual or constructive knowledge of any director or officer of Seller and Parent, after due inquiry.

 

Section 4.01
Organization and Authority of Buyer; Enforceability. Each of Seller and Parent is a corporation duly organized, validly existing and
in good standing under the laws of the state of their organization. Each of Seller and Parent has full corporate power and authority to
enter into this Agreement and the documents to be delivered hereunder, to carry out its obligations hereunder and to consummate the transactions
contemplated hereby. The execution, delivery and performance by Seller and Parent of this Agreement and the documents to be delivered
hereunder and the consummation of the transactions contemplated hereby have been duly authorized by all requisite corporate action on
the part of Seller and Parent. This Agreement and the documents to be delivered hereunder have been duly executed and delivered by Selleer
and Parent, and (assuming due authorization, execution and delivery by any Buyer Party) this Agreement and the documents to be delivered
hereunder constitute legal, valid and binding obligations of Seller and Parent and enforceable against them in accordance with their respective
terms.

 

    6

     

    

 

Section 4.02
Parent Capitalization; Valid Issuance. The entire authorized capital stock of the Parent, as at the date hereof, consists of 500,000,000
shares of common stock, par value $0.001 per share. All of the outstanding equity securities of the Parent have been duly authorized and
validly issued and are fully paid and non-assessable. None of the outstanding equity securities of the Parent were issued in violation
of any Applicable Securities Laws or any other Legal Requirement. The Parent does not own, or have any contract to acquire, any equity
securities or other securities of any Person, or any direct or indirect equity or ownership interest in any other business, other than
as contemplated by this Agreement. There are no contracts purporting to restrict the transfer of any of the issued and outstanding securities
of the Parent, nor any contracts restricting or affecting the voting of any of the securities of the Parent, to which the Parent is a
party or of which the Parent is aware. The Parent Shares to be issued at Closing will, upon issuance in accordance with the terms of this
Agreement, be duly and validly issued, fully paid and non-assessable, and will not be subject to any Lien or encumbrance.

 

Section 4.03
SEC Reports. As of their respective dates, the Parent’s filings with the Securities and Exchange Commission (the “SEC”)
(the “SEC Reports”) complied in all material respects with the requirements of the SEC. As of the time filed on EDGAR,
none of the SEC Reports contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.

 

Section 4.04
No Conflicts; Consents. The execution, delivery and performance by Seller and Parent of this Agreement and the documents to be delivered
hereunder, and the consummation of the transactions contemplated hereby, do not and will not: (a) violate or conflict with the certificate
of incorporation, by-laws or other organizational documents of Seller or Parent; or (b) violate or conflict with any judgment, order,
decree, statute, law, ordinance, rule or regulation applicable to Seller or Parent. No consent, approval, waiver or authorization is required
to be obtained by Seller or Parent from any person or entity (including any governmental authority) in connection with the execution,
delivery and performance by Seller or Parent of this Agreement and the consummation of the transactions contemplated hereby.

 

Section 4.05
Legal Proceedings. There is no Action of any nature pending or, to Seller's knowledge, threatened against or by Seller that challenges
or seeks to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement. No event has occurred or circumstances
exist that may give rise to, or serve as a basis for, any such Action.

 

Section 4.06
Brokers. No broker, finder or investment banker is entitled to any brokerage, finder's or other fee or commission in connection with
the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Seller.

 

    7

     

    

 

ARTICLE
V

COVENANTS

 

Section 5.01
Public Announcements. Unless otherwise required by applicable law or stock exchange requirements, neither party shall make any public
announcements regarding this Agreement or the transactions contemplated hereby without the prior written consent of the other party (which
consent shall not be unreasonably withheld or delayed).

 

Section 5.02
Bulk Sales Laws. The parties hereby waive compliance with the provisions of any bulk sales, bulk transfer or similar laws of any jurisdiction
that may otherwise be applicable with respect to the sale of any or all of the Purchased Assets to Buyer.

 

Section 5.03
Transfer Taxes. All transfer, documentary, sales, use, stamp, registration, value added, and other such taxes and fees (including
any penalties and interest) incurred in connection with this Agreement and the documents to be delivered hereunder shall be borne and
paid by Buyer when due. Seller shall, at Seller’s own expense, timely file any tax return or other document with respect to taxes
or fees applicable to Seller’s capital gain or other taxable event (and Buyer shall cooperate with respect thereto as necessary).
For avoidance of any doubt, no provision in this Agreement is intended to modify, cancel or suspend the Tax Indemnification, and the Tax
Indemnification remains in full force and effect.

 

Section 5.05
Further Assurances. Following the Closing, each of the parties hereto shall execute and deliver such additional documents, instruments,
conveyances and assurances and take such further actions as may be reasonably required to carry out the provisions hereof and give effect
to the transactions contemplated by this Agreement and the documents to be delivered hereunder.

 

ARTICLE
VI 

INDEMNIFICATION

 

Section 6.01
Survival. All representations, warranties, covenants and agreements contained herein and all related rights to indemnification shall
survive the Closing.

 

Section 6.02
Indemnification by Seller. Seller shall defend, indemnify and hold harmless the Buyer Parties, their affiliates and their respective
stockholders, directors, officers and employees from and against all claims, judgments, damages, liabilities, settlements, losses, costs
and expenses, including attorneys' fees and disbursements, arising from or relating to:

 

		(a)	any inaccuracy in or breach of any of the representations or
warranties of Seller contained in this Agreement or any document to be delivered hereunder;

 

		(b)	any breach or non-fulfillment of any covenant, agreement or
obligation to be performed by Seller pursuant to this Agreement or any document to be delivered hereunder; or

 

    8

     

    

 

Section 6.03
Indemnification by Buyer Parties. Each of the Buyer Parties shall defend, indemnify and hold harmless Seller, Parent, their affiliates
and their respective members, stockholders, directors, officers and employees from and against all claims, judgments, damages, liabilities,
settlements, losses, costs and expenses, including attorneys' fees and disbursements, arising from or relating to:

 

		(a)	any inaccuracy in or breach of any of the representations or
warranties of Buyer Parties contained in this Agreement or any document to be delivered hereunder;

 

		(b)	any breach or non-fulfillment of any covenant, agreement or
obligation to be performed by Buyer Parties pursuant to this Agreement or any document to be delivered hereunder; or

 

		(c)	any Assumed Liability.

 

Section 6.04
Indemnification Procedures. Whenever any claim shall arise for indemnification hereunder, the party entitled to indemnification (the
"Indemnified Party") shall promptly provide written notice of such claim to the other party (the "Indemnifying
Party"). In connection with any claim giving rise to indemnity hereunder resulting from or arising out of any Action by a person
or entity who is not a party to this Agreement, the Indemnifying Party, at its sole cost and expense and upon written notice to the Indemnified
Party, may assume the defense of any such Action with counsel reasonably satisfactory to the Indemnified Party. The Indemnified Party
shall be entitled to participate in the defense of any such Action, with its counsel and at its own cost and expense. If the Indemnifying
Party does not assume the defense of any such Action, the Indemnified Party may, but shall not be obligated to, defend against such Action
in such manner as it may deem appropriate, including, but not limited to, settling such Action, after giving notice of it to the Indemnifying
Party, on such terms as the Indemnified Party may deem appropriate and no action taken by the Indemnified Party in accordance with such
defense and settlement shall relieve the Indemnifying Party of its indemnification obligations herein provided with respect to any damages
resulting therefrom. The Indemnifying Party shall not settle any Action without the Indemnified Party's prior written consent (which consent
shall not be unreasonably withheld or delayed).

 

Section 6.05
Tax Treatment of Indemnification Payments. All indemnification payments made by Seller under this Agreement shall be treated by the
parties as an adjustment to the Purchase Price for tax purposes, unless otherwise required by law.

 

Section 6.06
Cumulative Remedies. The rights and remedies provided in this Article ARTICLE VI are cumulative and are in addition to and not in
substitution for any other rights and remedies available at law or in equity or otherwise.

 

    9

     

    

 

ARTICLE
VII

MISCELLANEOUS

 

Section 7.01
Expenses. All costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid
by the party incurring such costs and expenses.

 

Section 7.02
Notices. All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall
be deemed to have been given (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if
sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by facsimile or e-mail of a PDF document (with
confirmation of transmission) if sent during normal business hours of the recipient, and on the next business day if sent after normal
business hours of the recipient; or (d) on the third day after the date mailed, by certified or registered mail, return receipt requested,
postage prepaid. Such communications must be sent to the respective parties at the following addresses (or at such other address for a
party as shall be specified in a notice given in accordance with this Section 7.02):

 

	If to any of the Buyer Parties:	 	
    CMI LLC

    866 Navajo St, Denver, CO 80204

    E-mail: juanpepeholdings@gmail.com 

Attention: John Knapp

     

    Alternate email: mandyprice@goodmeds,com

	
     

    If to Seller or Parent:
	 	
     

    Cryomass Technologies Inc

    1001 Bannock St Suite 612 Denver Co 80204 USA

    E-mail: p.kovacevic@cryomass.com

    Attention: Patricia Kovacevic, General Counsel and Head
    of External Affairs

     

    With a copy to:

     

    Franc Del Fosse, Esq. 

Ballard Spahr LLP

    1 E. Washington Street, Suite 2300

    Phoenix, Arizona 85004

     

    Email: delfossef@ballardspahr.com

 

Section 7.03
Headings. The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.

 

    10

     

    

 

Section 7.04
Severability. If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity,
illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such
term or provision in any other jurisdiction.

 

Section 7.05
Entire Agreement. This Agreement and the documents to be delivered hereunder constitute the sole and entire agreement of the parties
to this Agreement with respect to the subject matter contained herein, and supersede all prior and contemporaneous understandings and
agreements, both written and oral, with respect to such subject matter.

 

Section 7.06
Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective
successors and permitted assigns. Seller or Parent may assign its rights and obligations hereunder without any duty to inform the Parties
and without the consent of the other parties. No assignment shall relieve the assigning party of any of its obligations hereunder.

 

Section 7.07
No Third-party Beneficiaries. Except as provided in ARTICLE VII, this Agreement is for the sole benefit of the parties hereto and
their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other
person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

 

Section 7.08
Amendment and Modification. This Agreement may only be amended, modified or supplemented by an agreement in writing signed by each
party hereto.

 

Section 7.09
Waiver. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed
by the party so waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default
not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that
waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate
or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude
any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

 

Section 7.10
Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Colorado without
giving effect to any choice or conflict of law provision or rule (whether of the State of Colorado or any other jurisdiction).

 

Section 7.11
Submission to Jurisdiction. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated
hereby may be instituted in the federal courts of the United States of America or the courts of the State of Colorado in each case located
in the city of Denver, and each party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding.

 

Section 7.12
Waiver of Jury Trial. Each party acknowledges and agrees that any controversy which may arise under this Agreement is likely to involve
complicated and difficult issues and, therefore, each such party irrevocably and unconditionally waives any right it may have to a trial
by jury in respect of any legal action arising out of or relating to this Agreement or the transactions contemplated hereby.

 

    11

     

    

 

Section 7.13
Specific Performance. The parties agree that irreparable damage would occur if any provision of this Agreement were not performed
in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to
any other remedy to which they are entitled at law or in equity.

 

Section 7.14
Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together
shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic
transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

 

[SIGNATURE PAGE FOLLOWS]

 

    12

     

    

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement
to be executed as of the date first written above by their respective officers thereunto duly authorized.

 

	CRITICAL
MASS INDUSTRIES, INC.	 	CRITICAL MASS INDUSTRIES LLC
	 	 	 	 	 
	By	 	 	By	 
	 	Name: John Knapp	 	 	Name: John Knapp
	 	Title: Authorized Signatory	 	 	Title: Authorized Signatory
	 	 	 	 	 
	JOHN KNAPP	 	GOOD MEDS, INC.
	 	 	 	 	 
	 	 	By	 
	John Knapp	 	 	Name: Philip Blair Mullin 
	 	 	 	 	Title: Authorized Signatory
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	CRYOMASS TECHNOLOGIES INC
	 	 	 	 	 
	 	 	 	By	 
	 	 	 	 	Name: Philip Blair Mullin
	 	 	 	 	Title: Chief Financial Officer

 

    13

     

    

 

DISCLOSURE SCHEDULES

 

Section 1. 01

 

Purchased Assets

 

In consideration for the transaction contemplated hereunder, Seller
shall transfer to Buyer any and all manufacturing, grow equipment, retail-related assets and other assets Seller owns in the state of
Colorado and are currently used by CMI subsidiaries in the course of business, including client lists and appertaining intellectual property,
and no other Buyer or Parent assets.

 

Section 1. 02

 

Assumption of Liabilities

 

Buyer assumes all liabilities related to the acquisition of
the Purchased Assets and no other liabilities.

 

    14

     

    

 

 

Exhibit A

 

SECURED PROMISSORY NOTE

 

 

On the 31st day of December, 2021,
hereinafter known as the "Start Date", CMI LLC with its registered address at 866 Navajo St, Denver, CO 80204, hereinafter
known as the “Borrower”, has received and promises to payback Good Meds Inc, a Colorado entity with registered address at
1001 Bannock St Suite 612 Denver CO 80204 or its successors or assigns, hereinafter known as the “Lender”, the principal sum
of six million US Dollars ($6,000,000), hereinafter known as the "Borrowed Money", beginning as of the Start Date
in the manner as follows:

 

1. PAYMENTS: The full balance of this
Note is due and payable on the 31st day of December, 2023, hereinafter known as the "Due Date". Payment shall be made
in a lump sum. There shall be no interest if paid in full on or before the Due Date. Partial payments shall be made promptly following
any disposal of Buyer Parties’ assets.

 

2. SECURITY: There shall be Property
described as all the assets, tangible or intangible, receivables, bank accounts, hereinafter known as the “Security”,
which shall transfer to the possession and ownership of the Lender IMMEDIATELY pursuant to Section 6A of this Note. The
Security may not be sold or transferred without the Lender’s consent until the Due Date. If Borrower breaches this provision,
Lender may declare all sums due under this Note immediately due and payable, unless prohibited by applicable law. The Lender shall
have the sole-option to accept the Security as full-payment for the Borrowed Money without further liabilities or obligations. If
the market value of the Security does not exceed the Borrowed Money, the Borrower shall remain liable for the balance due while
accruing interest at the maximum rate allowed by law.

 

3. INTEREST DUE IN THE EVENT OF DEFAULT:
In the event the Borrower fails to pay the note in-full on the Due Date, unpaid principal shall accrue interest at the maximum rate allowed
by law, until the Borrower is no longer in default. 

 

4. ALLOCATION OF PAYMENTS: Payments shall
be first credited any late fees due, then to interest due and any remainder will be credited to principal.

 

5. PREPAYMENT: Borrower may pre-pay this
Note without penalty.

 

6. ACCELERATION: If the Borrower is
in default under this Note or is in default under another provision of this Note, and such default is not cured within the minimum
allotted time by law after written notice of such default, then Lender may, at its option and in its sole discretion, declare all
outstanding sums owed on this Note to be immediately due and payable.

 

6A. SECURITY - This includes
any rights of possession in relation to the Security described in Section 2.

 

7. ATTORNEYS’ FEES AND COSTS: Borrower
shall pay all costs incurred by Lender in collecting sums due under this Note after a default, including reasonable attorneys’ fees.
If Lender or Borrower sues to enforce this Note or obtain a declaration of its rights hereunder, the prevailing party in any such proceeding
shall be entitled to recover its reasonable attorneys’ fees and costs incurred in the proceeding (including those incurred in any
bankruptcy proceeding or appeal) from the non-prevailing party.

 

    15

     

    

 

8. WAIVER OF PRESENTMENTS: Borrower waives
presentment for payment, notice of dishonor, protest and notice of protest.

 

9. NON-WAIVER: No failure or delay by Lender
in exercising Lender’s rights under this Note shall be considered a waiver of such rights.

 

10. SEVERABILITY: In the event that any
provision herein is determined to be void or unenforceable for any reason, such determination shall not affect the validity or enforceability
of any other provision, all of which shall remain in full force and effect.

 

11. INTEGRATION: There are no verbal or
other agreements which modify or affect the terms of this Note. This Note may not be modified or amended except by written agreement signed
by Borrower and Lender.

 

12. CONFLICTING TERMS: The terms of this
Note shall control over any conflicting terms in any referenced agreement or document.

 

13. NOTICE: Any notices required or permitted
to be given hereunder shall be given in writing and shall be delivered (a) in person, (b) by certified mail, postage prepaid, return receipt
requested, (c) by facsimile, or (d) by a commercial overnight courier that guarantees next day delivery and provides a receipt, and such
notices shall be made to the parties at the addresses listed below.

 

14. EXECUTION: The Borrower executes this
Note as a principal and not as a surety.

 

16. GOVERNING LAW: This note shall be governed
under the laws in the State of Colorado.

 

17. SIGNATURE AREA

 

 

	Lender	 	Borrower
	 	 	 
	Good Meds Inc	 	CMI LLC
	 	 	 
	 	 	 
	 	 	 
	By: Philip Blair Mullin	 	By: John Knapp
	Authorized Signatory	 	Authorized Signatory
	Date: December 31, 2021	 	Date: December 31, 2021
	 	 	 
	Witnessed by	 	 
	 	 	 
	Patricia Kovacevic	 	 
	 	 	 
		 	 Date: December 31, 2021

 

 

16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]